Olaparib
Ovarian Endometrioid Adenocarcinoma
Floatz Rating
BB70/100
Confidence
Indicative
Sponsor
University of Colorado, Denver
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06856499CT.gov Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer | — | Recruiting | — | — | — |
NCT06580314CT.gov Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer | — | Recruiting | — | — | — |
NCT05295589CT.gov Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy | — | Withdrawn | — | — | — |
NCT04739800CT.gov Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents | — | Active Not Recruiting | — | — | — |
NCT03924245CT.gov Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers | — | Terminated | — | — | — |
NCT04034927CT.gov Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer | — | Active Not Recruiting | — | — | — |
NCT02345265CT.gov Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer | — | Active Not Recruiting | — | — | — |
NCT02502266CT.gov Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer | — | Active Not Recruiting | — | — | — |
NCT02446600CT.gov Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | — | Active Not Recruiting | — | — | — |
NCT01116648CT.gov Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Endometrioid Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Olaparib (this asset) | University of Colorado, Denver | P3 | BB · 70 |
| Carboplatin | National Cancer Institute (NCI) | P3 | BBB |
| Adriamycin | National Cancer Institute (NCI) | P3 | BB |
| Cyclophosphamide | Roswell Park Cancer Institute | P2 | BB |
| Multi-Epitope Folate Receptor Alpha-Loaded Dendritic Cell Vaccine | Mayo Clinic | P2 | BB |
| Cis-Diamminedichloroplatinum Ii | Genelux Corporation | P3 | BB |
| Pembrolizumab | Roswell Park Cancer Institute | P2 | BB |
| Cediranib | National Cancer Institute (NCI) | P3 | BB |
| Atezolizumab | University Health Network, Toronto | P2/3 | B |
+42 more in the Ovarian Endometrioid Adenocarcinoma cohort
Other indications for Olaparib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P4 | BBB · 73 |
| Fallopian Tube Serous Adenocarcinoma | — | P3 | BBB · 72 |
| Ovarian Carcinoma | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Olaparib in Ovarian Endometrioid Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/olaparib-ovarian-endometrioid-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →